Research programme: RhoB modulators - Evotec/Inserm Transfert

Drug Profile

Research programme: RhoB modulators - Evotec/Inserm Transfert

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evotec AG; Inserm Transfert
  • Class
  • Mechanism of Action Rho-associated kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 22 Sep 2016 Early research in Cancer in France, Germany (unspecified route)
  • 22 Sep 2016 Evotec and Inserm Transfert agree to co-develop drugs by targeting RhoB for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top